# Anti-SARS Cov-2 T Cell Infusions for COVID 19

> **NCT04401410** · PHASE1 · TERMINATED · sponsor: **Baylor College of Medicine** · enrollment: 4 (actual)

## Conditions studied

- SARS-CoV 2
- Viral Infection
- COVID 19

## Interventions

- **BIOLOGICAL:** Dose Finding Phase (MTD)
- **BIOLOGICAL:** Partially HLA-matched SARS-CoVSTs
- **OTHER:** Routine care (no SARS-CoVSTs)

## Key facts

- **NCT ID:** NCT04401410
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-04
- **Primary completion:** 2021-10-12
- **Final completion:** 2021-10-12
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Due to trial's eligibility criteria and the low census of hospitalized COVID-19 patients meeting eligibility criteria, the Sponsor will be unable to enroll a meaningful number of patients in this single-center trial in a reasonable time frame.
- **Last updated:** 2022-12-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04401410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04401410, "Anti-SARS Cov-2 T Cell Infusions for COVID 19". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04401410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*